2012 Current Cancer Dedicated to bringing the latest news and information on cancer diagnosis, treatment and prevention.

Gentel Biosciences, a leader in proteomics profiling tools, announces the availability of thirteen APiX™ Human Tumor Profiling Kits, robust tissue-lysate (reverse-phase) protein arrays and chromogenic-based detection reagents, suitable for the testing of putative protein biomarkers in over thirteen cancer subtypes.
“This product launch continues to expand the portfolio of APiX kits to include clinically relevant tissue lysate arrays”
The new kits combine Gentel’s APiX™ chromogenic detection technology and Protein Biotechnologies, Inc.’s large collection of ready-to-use, clinically-defined, pathology-validated normal and diseased human tissue collection for the study of protein expression differences in patient sample sets. Each kit is configured for use with the Gentel Proteomics Multi-System™ and Gentel’s AthenaQuant® analysis software for an easy-to-use and cost-effective alternative to fluorescent and chemiluminescent-based detection. The all-inclusive, “sample-into-data” workflow empowers both experts and novices with the necessary tools to conduct an experiment and obtain meaningful proteomics data in a single day.
“This product launch continues to expand the portfolio of APiX kits to include clinically relevant tissue lysate arrays”, said Alex Vodenlich, Gentel’s President and CEO. “We’re responding to the market’s need for technologies that enable rapid screening of patient specimens for the abundance of potential protein biomarkers. This ability has broad applications in biological and biomedical research and is ideally suited for screening known and novel cancer-related protein biomarkers. The product line is relevant for use in testing cancer-research hypotheses with a large number of well characterized clinical-case samples, as statistical significance confirmation is a key validation step in late stage in vitro studies”, he continued.
The APiX™ Human Tumor Profiling Kits are second in a series of high-value products and services that Gentel is commercializing in the second half of 2010. As an introduction to the technology, Gentel will provide scanning and data reporting for each new customer’s initial kit purchase. To learn more about the thirteen APiX™ Human Tumor Profiling Kits, see how they augment your proteomics-research workflow and find out how to take advantage of the free “scan and report” service offer, please visit here.

Source:
Gentel Biosciences, Inc.

Related Search